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Abstract
Objectives
This cross-sectional study aimed to evaluate the prevalence and type of oral HPV-infection in
women with a cervical HPV-lesion and in the oral and genital mucosa of their male partners.
Methods
The study group comprised 44 sexually-active women, 20–45 years with abnormal PAP
smear, not more than 6 months prior to referral together with the male partners cohabiting in
stable partnerships. A detailed questionnaire was administered concerning the HPV-related
risk factors. Oral swabs, oral rinses, cervical swabs and urine samples were collected. HPV
DNA was detected using two different polymerase chain reactions (PCRs): MY09-11 and
FAP59-64. Positive samples were genotyped by Sanger sequencing and the INNO-LiPA
HPV Genotyping Extra II probe assay. The association with risk factors was assessed by fit-
ting a generalized model, using the General Linear Model function in the R-software; corre-
lations were calculated between all data.
Results
HPV was detected in 84% of Cervical Samples, in 24.3% of oral samples and in one urine
sample. Only 27% of the HPV-positive results were identical with both PCR DNA assays.
8 male had oral HPV-positive samples different from women cervical samples. In one
couple the urine-male sample had the same HPV present in the female-cervical sample. A
significant association resulted between women/oral sex practices and men/n. of partners.
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Conclusions
This study reports that women (20.4%) with a diagnosis of cervical-HPV and their male part-
ners (30,7%) are at high risk for subclinical oral HPV infection.
Introduction
The incidence of head and neck cancer has changed dramatically over the last 30 years. Prior
to that time, the commonest of these cancers, squamous cell carcinoma, generally occurred in
older adults with a history of tobacco and alcohol use. While smoking-related head and neck
cancers have been declining overall, squamous cell carcinoma of the oropharynx has been
increasing in many developed countries, including Australia, Canada, Denmark, Japan, Nor-
way, Sweden, Netherlands, and United Kingdom [1–5]. Today, patients diagnosed with head
and neck squamous cell carcinoma (HNSCC) are more likely to be adults in their 40s and 50s
who have never smoked or used other tobacco products. These changes are chiefly due to the
human papillomavirus (HPV) [6].
Recent advances in molecular techniques have progressively identified novel HPV-types
and sub-genomic HPV sequences [7] and more than 200 different HPV-types are now recog-
nized by the International HPV Reference Center. HPV is the most common sexually trans-
mitted infection (STI), making up over half of all new and existing STIs [8]. The majority of
adults will become infected at some point in life, with no symptoms whatsoever; the body’s
immune system generally eliminates the infection. In approximately 1% of adults, HPV-16,
the type most commonly associated with head and neck cancer, is detectable in the saliva [9].
HPV is mainly known for its association with benign (non-cancerous) lesions, such as genital
warts, and it has long been recognized in association with cervical cancer. Today, HPV is the
most common cause of oropharyngeal cancer (OC), presenting different symptoms from
HPV-negative cancers: neck mass, sore throat, and fewer than 15% of subjects report a visible
oral lesion [10]. HPV-positive OC are 3 to 5 times more common among men than women.
[1, 11]
In view of the association among HPV, cervix uteri, and OC, HPV-positive OC has been
considered to be a sexually transmitted disease, and the HPV-positive cervix to act as a virus
reservoir [12]. Other studies have found that a history of cervical dysplasia or abnormal PAP-
smears in women increased the risk of HPV-positive oral cancer in their male partners [9, 13].
However, there is still no consensus on these matters, nor on the relationship between genital
and oral HPV-infection.
In view of these inconsistent data, the present cross-sectional study aimed to evaluate the
prevalence and type distribution of oral HPV-infection in Italian immunocompetent women
with a known cervical HPV-related lesion (abnormal PAP-smear) and in the oral and genital
mucosa of their monogamous male partners.
Materials and methods
Ethics statement
The study, performed between March 2015 and May 2016, was approved by the Ethics Com-
mittee of the Fondazione IRCCS Ca’ Granda-OSPEDALE MAGGIORE POLICLINICO,Milan
(Prot. n. 2765). All participants agreed to participate in the research and signed their informed
consent. All data were analyzed anonymously.
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Study population
The initial study group comprised 106 sexually-active adult women, aged 20–45 years, who
had been referred to the U.O. Ostetricia e Ginecologia-Centro di riferimento per la preven-
zione, la diagnosi e la cura della patologia genitale HPV-correlate, Fondazione IRCCS Cà-
Granda Ospedale Maggiore Policlinico—Milano, after an abnormal PAP smear, not more
than 6 months prior to referral, within a cervical screening program with routine clinical
and cyto/histological examination, together with the male partners of some of these women,
cohabiting in stable partnerships (S1 Table). Exclusions were: 7 women for drug use or illness
(immunosuppresors/antibiotics for HIV/oral infection), 15 women for incomplete or inade-
quate samples; 40 women and 2 men refused to enter the study. The final study group com-
prised 44 women and 26 male partners. Participants received a free clinical examination of the
oral cavity and were evaluated by a trained oral clinician for clinical examination of the oral
mucosa and cytological sampling at the Department of Biomedical, Surgical and Dental Sci-
ences, UOC Chirurgia Maxillo-Facciale e Odontostomatologia of the above hospital. A
detailed questionnaire was administered, addressing sexual practices, socio-economic and
health status. In particular it concerned personal information (gender, age, education, marital
status, pregnancies); medical history (oral or cervical lesions, type of lesion, HPV vaccination
status, other cervical infections); known cofactors associated with the risk of developing high-
grade squamous intraepithelial lesions (smoking and drinking); sexual behavior (age of first
sexual intercourse, number of partners in the last year, frequency of sexual intercourse, use of
birth control, practice of oral sex). (S2 Table)
Data and sample collection
Oral swabs, oral rinses and cervical swabs were collected from the women; oral swabs, oral
rinses, and urine samples were collected from their partners. Cervical swabs were collected
using a brush. Oral rinses were obtained by rinsing the mouth with 10-15ml of water and spit-
ting the rinse into a tube. Oral swabs were collected both from the buccal mucosa and the sur-
face of the tongue using a specific swab (ORAcollect-DNA kit; DNA-genotek Inc.). Urine
samples were collected using conventional sterile tubes. All samples were immediately frozen
at -20˚C.
DNA extraction
Papillomavirus DNA was extracted from four different matrices: cervical swab (CS), urine (U),
oral swab (OS) and oral rinse (OR). DNA from OS was extracted using the prepIT DNA
extraction kit (DNAGenotek), for CS, U and OR samples, the “NucleoSpin Virus, Viral RNA
and DNA isolation” kit (Macherey-Nagel) was used. Briefly, prior to sample lyses, CS samples
were incubated in 500ul of sterile PBS at room temperature for 1 hour; 200ul of PBS were then
used for DNA extraction. U and OR samples were thawed overnight at 4˚C, then 3 ml of sam-
ple were centrifuged at 13,000 xg for 10 min. The pellet was resuspended in 200ul of sterile
PBS and the DNA extraction protocol was applied. The resulting DNA was stored at -20˚C
until testing.
HPV detection and genotyping
The presence of human DNA in all samples was confirmed by amplifying the ALAS1 (5’-Ami-
nolevulinate Synthase 1) gene (Bishop et al Genomics 1990). HPV DNA was detected using
two different polymerase chain reactions (PCRs) targeting the HPV L1 region:i) MY09-
11_HPV PCR assay and ii) FAP59-64_HPV PCR assays using respectively degenerate primers
Prevalence of oral and genital HPV in Italian couples
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MY09 5'-GCMCAGGGWCATAATAATGG 3'MY11 5' CGTCCMARRGGAWACTGATC 3' to
amplify a 450 bp fragment (Gravitt et al. 2000) and FAP59 5'TAACWGTIGGICAYCCWTATT
3') and FAP64 5'CCWATATCWVHCATITCICCATC-3' to amplify a fragment of about 480
bp (Forslund et al. 1999). The HPV DNA positive samples were subsequently genotyped by
Sanger sequencing on the 3730xl DNA Analyzer (Applied Biosystems). Sequence traces from
HPV DNA samples were aligned to the genomic sequence (PAVE Papilloma Virus Reference
database or NCBI nucleotide database). The INNO-LiPA HPV Genotyping Extra II probe
assay, based on the principle of reverse hybridization, was thus used to genotype the human
HPV in samples with multiple HPV-infections. The following HPV genotypes can bedetected
and identified: HPV 16, 18, 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 68; 26, 53, 66, 70, 73, 82; 6, 11,
40, 42, 43, 44, 54, 61, 62, 67, 81, 83, 89. (Fig 1)
Statistical analyses
Variables considered for statistical analyses were: gender, age, number of partners, oral sex,
alcohol consumption per week, cervical lesions, pregnancy, vaccination, education, civil status,
Fig 1. Molecular work flow.
https://doi.org/10.1371/journal.pone.0205574.g001
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smoking, frequency of sexual intercourse, contraceptive use, other cervical lesions, age at first
intercourse. Before analyzing the data, intervals were constructed for some variables: age,
infection, alcohol consumption, and smoking. The effect of the variables on the HPV-infection
status was assessed by fitting a generalized model, using the GLM (General Linear Model)
function in the R software. The family “binomial” was used to describe the error distribution
and link function. As the number of samples was relatively small, the R fisher.test function was
used to perform Fisher’s exact test for verification. The model was tested using the maximum
likelihood to evaluate the effect of inclusion of each parameter on the model. As supplemen-
tary analysis, the correlations were calculated between all parameters.
Results
Distribution of HPV infection in the study population (Table 1)
Human genomic DNA corresponding to the ALAS1 (5’-Aminolevulinate Synthase) gene was
detected in all samples (cervical swab, oral samples and urine). Only one cervical swab was
inadequate.
Female—Cervical swab infection. HPV DNA was detected in 84% (n.36/43) of CS sam-
ples using the MY09-MY11_HPV DNA assay and/or the FAP59-FAP64_HPV DNA assay.
The percentages of HPV-positive CS samples found with the two different PCR assays are in
Table 1. Only 69.7% of the HPV PCR results were identical (positive/positive; negative/nega-
tive) with the two assays while 16% of the results were discordant (e.g. positive/negative;
doubtful/positive; doubtful/negative) and 14% were concordant but not identical (e.g. weakly
positive/positive). S3 Table
Male and female—Oral sample infection (OR+OS). HPV DNA was detected in 24.3% of
oral samples. An oral sample was considered positive if HPV DNA was detected in OS or OR
using the MY09-11_HPV and/or the FAP59-64_HPV PCR assays (S3 Table). In particular
HPV DNA was present in 20.4% of women with a diagnosis of cervical-HPV and 30.7% of
male. Moreover HPV DNA was present in 18,6% of OS and in 10% of OR (male+female)
using the MY09-11 (see Table 1). Considering the OS samples, only 75.6% of the HPV DNA
results were identical with the two assays; 18.6% of results were discordant.1.3 Male—Urine
samples.
HPV DNA was detected in only one sample (S3 Table).
Genotyping
Female—Cervical swab samples. All positive HPV DNA CS samples (Fig 2) were geno-
typed by sequencing. Only 27% of the HPV genotyping results were clearly identical with both
PCR DNA assays (e.g. HPV type 16 with both assays). In some cases the HPV genotyping
results were different (e.g. HPV type 33 amplified with MY09-11 PCR assay and HPV type 68
with FAP59-64 assay). In other cases only using one of both PCR assays was possible character-
ize the HPV type in a sample (S3 Table). The percentage of multiple infections was 18% with
Table 1. Percentage of cervical swab (n. 43), oral swab (n. 70) or oral rinse (n.70) samples that were positive (P), doubtful (D) or negative (N) for the presence of
HPV DNA using MY09-11 HPV, FAP59-64, or both HPV PCR assays.
Cervical Swab (n. 43) Oral Swab (n. 70) Oral Rinse (n.70)
% P % D % N % P % D % N % P % D % N
MY09-11 81 0 19 18.6 2.9 78.5 10 0 90
FAP59-64 70 9 21 0 5,7 94.3 1 0 99
Both assays 84 0 16 20 2.9 78.5 10 0 90
https://doi.org/10.1371/journal.pone.0205574.t001
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the MY09-11 PCR assay and 35% with the FAP59-64 assay, and was 45% if both assays were
considered. The INNO-LiPA HPV Genotyping Extra II probe assay was used in samples
infected with multiple HPV types. HPV16 was the most frequent HPV type in CS samples.
Male and female—Oral samples (OR+OS). All positive HPV DNA oral samples were
genotyped by sequencing. The sequences obtained using the MY09-11 PCR assay gave more
complete results than those obtained using the FAP59-64 PCR assay: only one sample that was
positive using the FAP59-64 PCR DNA assay was genotyped (HPV type 147). All oral samples
were genotyped using the MY09-11 PCR assay (Fig 3). There were no oral samples with multi-
ple infections, with one exception: HPV147 with the FAP59-FAP64 PCR DNA assay and HPV
type 33 with the MY09-MY11 PCR assay. HPV33 was the most frequent HPV type in oral
samples.
Fig 2. Prevalence of HPV genotype in CS samples using MY09-MY11, FAP59-FAP64, or INNO-LiPA HPV
Genotyping Extra II probe assays; HPV genotype (X-axis) and percentage of HPV genotype (y-axis).
https://doi.org/10.1371/journal.pone.0205574.g002
Fig 3. HPV genotyping: Percentage of HPV type in oral samples using MY09-MY11, FAP59-FAP64, or
INNO-LiPA HPV Genotyping Extra II probe assays.
https://doi.org/10.1371/journal.pone.0205574.g003
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HPV concordance in women (both in cervix and oral cavity, Table 2)
16% (7/43) of the oral samples from CS-HPV-positive women were positive. The HPV geno-
type in the oral sample was different from that in the CS sample for patients no. 10,39 and 72.
The same HPV06 was detected in patient 55. The HPV-types in patients 33, 41 and 68 are
unfortunately not included in the list of HPV-types detected by the INNO-LiPA HPV Geno-
typing Extra II probe assay.
HPV transmission between partners: Inter-transmission (Table 3)
A total of 25 couples were analyzed. 21 women had HPV-positive CS; 4 had HPV-negative CS
and their partners had HPV-negative oral samples.
9 male partners had HPV-positive samples (8 Oral samples and 1 US). In couple no 15, the
male had US with the same HPV61-type present in the CS sample. In the other couples, the
HPV type in the CS sample differed from that in the male sample.
In couple no. 22, the male OS was positive for HPV84, which unfortunately is not on the
list of HPV-types detected by the INNO-LiPA HPV Genotyping Extra II probe assay.
Statistical analysis
The regression of variables against total infection status highlighted three significant factors:
gender, oral sex, and alcohol (p = 0.000224, 0.0119, and 0.0362, respectively). This shows that
Table 2. HPV type in women with both oral and cervical swab (CS) samples positive for HPV.
Woman
patient
Oral Tot Genotype Cervical Swab (CS) Genotype
10 HPV33 HPV control 1; HPV control 2; HPV16; HPV31; HPV51;HPV52
33 HPV-RTRX3-like L1
gene
HPV control 1; HPV control 2
39 HPV62 HPV59
41 HPV22 HPV control 1; HPV61; HPV89
55 HPV6 HPV6
68 HPV145 HPV control 1; HPV control 2; HPV16; HPV31; HPV39; HPV06;
HPV66; HPV62; HPV81
72 58 42
https://doi.org/10.1371/journal.pone.0205574.t002
Table 3. HPV data from couples with the woman’s cervical swab positive for HPV and the man’s oral samples or urine samples positive for HPV.
No. of
couples
Cervical Swab HPV DNA
(female)
Cervical Swab HPV Type (female) Oral HPV DNA
(male)
Oral HPV Type sanger
Sequencing (male)
Urine HPV DNA
(male)
3 Pos 39 pos 68 neg
4 Pos HPV control 1; HPV control 2; HPV16;
HPV31; HPV51;HPV52
pos 66 neg
5 Pos 16 pos 33/147 neg
15 Pos HPV control 1; HPV61; HPV89 neg n.a. pos�
17 Pos 68 pos 110 neg
18 Pos 66 pos 120 neg
19 Pos HPV control 1; HPV6 pos 33 neg
22 Pos HPV control 1; HPV51 pos 84 neg
24 Pos 43/52 pos 66 neg
�HPV type in US: HPV control 1; HPV control 2; HPV58;HPV61
https://doi.org/10.1371/journal.pone.0205574.t003
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there is a male-female difference with regard to HPV-infection; oral sex is determinant for
HPV-infection; alcohol consumption appears to have a negative effect on HPV-infection sta-
tus. Other variables, such as number of partners, frequency of intercourse, age, or use of birth
control, do not emerge as significant in this study.
In particular, the regression of these variables against oral infection status shows that gender
is a significant factor (p = 0.04517). Age and smoking came close to significance (p = 0.0885
and 0.0901, respectively). Oral sex and alcohol emerged as significant factors also for cervical
infections (p = 0.0492 and 0.0229, respectively) while number of partners, use of birth control,
smoking, and age appear not to affect cervical infections.
In a second phase of the study, the data were subdivided into male and female samples.
Two regressions were then performed using the two data-subsets. It emerged that oral sex is
highly significant in women for HPV-infection, but only indicatively significant in men. Oral
sex was three times more common in men than in women. Moreover, in men the number of
the partners and the frequency of intercourse tend to affect oral HPV-infection (p = 0.0514
and 0.08, respectively: approaching significance). As the sample is relatively small, the signifi-
cance of oral sex and alcohol was checked and confirmed using the Fisher exact test. Correla-
tions were also calculated between all parameters, leading to some important biological
considerations. Particularly, the correlation between oral sex and cervical infection was signifi-
cant (p = 0.04001).
Discussion
The diagnosis of cervical HPV-infection is not generally accompanied by investigations at dif-
ferent sites, such as the oral cavity, except in the presence of visible lesions. The present results
show that patients with genital HPV-infection are at risk for oral infection, not always associ-
ated with visible clinical lesions. The absence of clinical signs in the oral cavity suggests the
infection may be subclinical, and a molecular assay might thus be necessary to diagnose it.
Mixed HPV genotype infections are common, and there are 182 different Homo sapiens HPV
types in the Papilloma virus Genome Database (PaVE: https://pave.niaid.nih.gov/). Due to the
great variability of HPV types, two different HPV PCR assays were used, to amplify all geno-
types simultaneously and Sanger sequencing to identify all 182 types present in the HPV
database, and also SNP variants between the same HPV-types (e.g. the SNP variant between
different HPV 16 types). If the same HPV 16 subtype is present in the partner, a direct mecha-
nism of HPV transmission may be suggested. Moreover, SNP comparison is important to clar-
ify the genetic evolution of types over time, their carcinogenic properties, and to differentiate
re-infection from persistent infection [14]. Although Sanger technique is highly accurate,
samples with infection by multiple HPV-types cannot be genotyped without cloning so the
INNO-LiPA HPV Genotyping assay was for samples with multiple HPV-infections. However,
this method can only detect 32 HPV types, and does not detect SNP variability.
It is now known that HPV is present in up to 60% oropharyngeal squamous cell cancer
(OSCC), and a rise of HPV-associated to OSCC has recently been detected. The peculiarity of
this increase is that it runs counter to the decline in smoking, which was considered one of the
main risk factor associated with the development of this type of cancer.[15,16]
These trends are confirmed for the USA,[17] where HPV was detected in 16% of tonsillar
cancer samples between 1984 and 1989, against 73% between 2000 and 2014, as well as in
Europe[18], specifically Sweden, where it rose from 23% in the 1970s to 77% in 2003.
Research worldwide has attempted to elucidate HPV transmission rates to the oropharynx
and has recently focused upon the possible transmission from the cervix to a woman’s oral
mucosa and that of her partner (Table 4).
Prevalence of oral and genital HPV in Italian couples
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The main limit of these studies is that authors haven’t designed a research protocol as we
did considering both female and their stable partners, collecting different type of samples, the
use of different analyses technique and the association with other risk factors.
21 studies published between 1992 and 2017 have collected data from various countries[19–
39]. Subgroups are here considered, based on macro-geographic areas: 10 from Europe, 7
South America, 2 North America, 1 South Africa, 1 Asia/Malaysia. Four of the European stud-
ies were conducted in Italy[20,26,29,38]. Only 5 recent articles (4 in Europe and 1 in Brazil)
analyzed the oral mucosa of both female and male partners[35–39].
The pooled prevalence obtained from Table 4 (all countries) of oral HPV-infection in
women with cervical HPV-infection is 18.3%. In Europe, 955 women with HPV cervical infec-
tion have been evaluated, of whom 95 were positive (10%); in South America, of 424 women
188 were positive (44.3%). It appears to be important to consider different geographical areas
separately, due to the different results that might be associated with different socio-economic
and behavioral lifestyles.
Table 4. Concurrence of oropharyngeal HPV-screening studies. Summary of the transmission and concordance of HPV from cervix to oropharynx reported in the
literature.
Year References Country Women with
genital HPV
lesions
Male
Partner
F Oral
+ (%)
M Oral
+ (%)
Oral sampling
method
Oral
Genotypes
Notes/risk factors Method
2016 Uken [39] Germany 101 60 3 5 Brush 35, 41, 61, 84–
16, 18
Low transmission PCR
2016 Visalli [38] Italy 100 - 24 - Saliva
collection
16, 18, 45, 31 High risk cervical lesions PCR
2016 Kero [37] Finland 58 58 10,3 24,1 Brush 16, 6, 53, 56 Low genotype
concordance—Smoking,
oral sex practice
PCR
2015 Tatar[36] Hungary 40 34 20 17,6 Brush 16 PCR
2015 Marques [35] Brazil 43 22 2,3 13,6 Brush - PCR
2014 Vidotti [34] Brazil 105 - 23,8 - Brush - Genital infection PCR
2014 Meyer [33] Germany 70 5 5,7 0 Brush+Rinse 54, 84 Low transmission NestedPCR
2014 Fuster-Rossello
[32]
Argentina 30 - 30 - Brush 16, 52, 6 PCR
2013 Adamopoulou
[31]
Greece 29 - 17,2
58,6�
- Rinse 16, 31, 53, 73,
6, 77, 81, 84
PCR and
Nested PCR
2011 Peixoto [30] Brazil 100 - 81 - Brush - Alcohol PCR
2011 Termine [29] Italy 98 - 14,3 - Rinse 16, 3, 10, 107 Younger age sexual debut Nested PCR
2010 Saini [28] Malaysia 70 - 5,71 - Brush Only 13 HR hpv tested PCR
2010 Sanchez-Vargas
[27]
Mexico 46 - 100 - Brush 16 - PCR
2009 Termine [26] Italy 140 - 1,4 - Brush - Rinse better? Nested PCR
2009 Castro[25] Brazil 30 - 0 - Brush - - PCR
2008 Marais [24] South
Africa
72 - 23,6 - Brush 11, 28, 33, 68,
72
Low concordance Nested PCR
2006 Giraldo [23] Brazil 70 - 37,1 - Brush - Genital infection PCR
2006 Fakhry [22] USA 35 - 14,3 - Rinse 45, 83, 89, 72,
71, 62
Genital infection PCR
2004 Smith [21] USA 165 - 3,6 - Rinse 16, 31 - PCR
1998 Badaracco [20] Italy 10 - 50 - Brush - Only 10 subjects PCR
1992 Kellokoski [19] Finland 309 - 3,8 - Brush 6, 11, 16 - HY
https://doi.org/10.1371/journal.pone.0205574.t004
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With regard to the male samples, the difference is not significant: positivity is 14.6% in
Europe and 13.6% in South America. These data should be carefully interpreted due to
the small sample size and limited number of studies (22 subjects in South America, 157 in
Europe).
With regard to Italian studies, the pooled prevalence among a total cohort of 348 women
with cervical HPV-infection was 45 positive in the oral cavity. Among HPV-negative women
in Italy, the concurrence of HPV in both genital and oral mucosa was 12.9%[20,26,29,38]. The
positivity rate for women found here (20.4%) was higher than the world average (18.3%), the
European average (10%) and other Italian studies (12.9%).
No other Italian study investigated the presence of the virus in the oral mucosa of
male partners. As far as the present authors are aware, only 5 previous studies investigated
HPV transmission from the female cervix to the sexual partner’s oral mucosa. The present
study may be considered to be the first Italian study to investigate the presence of the virus
in the oral mucosa of stable male partners of women with genital infection. Thus these pre-
liminary results may only be compared with those from other countries (4 in Europe and 1
in Brazil), which reveal an overall cumulative rate of 14.5%, compared with 30.7% reported
here.
The association with different risk factors (alcohol consumption, smoking, no. of part-
ners, etc.) and other factors (use of condom, oral sex etc.) was examined in this study (S1
Table). For women, the results suggest a significant association with oral sex practices and
for men with increased number of partners. Study participants also underwent a complete
oral clinical examination, but no relevant clinical lesions were found; thus oral examination
alone cannot exclude the possibility of oral HPV-infection. Oral HPV-infection was mainly
sub-clinical.
Transmission of HPV to the oral cavity, and the consequent risk of oral cancer, is increased
in women with cervical infection and in their partners, suggesting the possible transmission
between oral cavity and genitals. The presence of the virus in these two anatomic sites could
be consequent upon genetic predisposition, conditions of low/altered immune response, the
host’s inability to develop an appropriate immune response. However, the viral concordance
between the two anatomical sites appears not to be mandatory.
Possible explanations for the different prevalence of HPV genotypes in the oropharynx ver-
sus the cervix might include different clearance mechanisms, host defense, or local cellular fac-
tors (lysozymes, amylase, lactoferrin, immunoglobulin a, etc.).
The presence of the virus in the genital mucosa of male partners’ urine samples was also
investigated. Only one positive sample was found (genotype 22); this was the same genotype
found in his female partner but no assumption may be based on a single case.
The main limits of this study are the small sample size and the absence of a control group;
these are two of the principal critical points common to other published studies. However,
some comparison with the healthy population may emerge from recent studies of children and
adults (women without cervical HPV-infection), that report oral prevalence of HPV ranging
between 2.5 and 9%[11, 29, 40].
The strengths of this research are the use of highly efficient and sensitive procedures for
oral sample collection (rinse+dedicated brush); the HPV detection with two different PCR
assays (FAP59-64 and MY09-11); the genotyping processing techniques used (Sanger+Inno-
Lipa); a molecular analyses able to detect each single SNP variant; the evaluation of the com-
presence of the virus in stable couples with cervical HPV-infection; a complete questionnaire
including all the main risk factors associated with HPV-infection; a review of the previous arti-
cles published. Further, this is one of the few studies that included the male partners of women
with cervical HPV-infection, and the first such Italian sample.
Prevalence of oral and genital HPV in Italian couples
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Conclusion
This study reports that women with a prior diagnosis of cervical HPV and their male partners
are at high risk for subclinical oral HPV, as indicated by the presence of the virus in the oral
cavity in 20.4% of female and in 30,7% of male. The pooled prevalence of oral HPV-infection
in women with cervical HPV-infection obtained from a review of the literature 1990–2016
was 10% (European average) and 12.9% in Italian studies. This is significantly higher than that
reported in the general population of women without cervical HPV-infection.
The same trend emerged in male samples: pooled published data gives a positivity of 14.5%,
whereas the present study found double this rate (30.7%). This might indicate that genital
HPV-infection is a predisposing condition to oral HPV-infection, in both women and their
male partners. However, the results should be interpreted cautiously, and larger cohorts must
be tested via multicentre and longitudinal studies to clarify viral transmission to/from the oral
mucosa.
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